What changed
What changedЧлен ради директорів Merck & Co., Inc. Томас Г. Глокер планує піти у відставку під час щорічних зборів акціонерів у травні 2027 року. Компанія підтвердила, що це рішення не пов'язане з жодними розбіжностями щодо її операцій чи політики.

What changedMerck & Co., Inc. reported third-quarter 2026 results with earnings per share (EPS) of $2.04 under generally accepted accounting principles (GAAP) and $2.49 on a non-GAAP basis. The quarter included a $400 million one-time charge for a new license agreement and lower revenue from the Koselugo alliance, which followed a 2025 contract restructuring.

What changedOn October 13, 2026 Merck & Co., Inc. announced that Paul J. Diaz, managing partner of Cressey & Company, will join the board of directors on November 1, 2026, increasing the board to 14 members; he will serve on the audit and research committees and will receive standard compensation without conflicting agreements.

Company history
October 2026
Merck & Co., Inc. appointed a new director, released third-quarter 2026 financial results, and reported several clinical and regulatory developments in October 2026.
- On October 13, 2026, the company announced that Paul J. Diaz was appointed to the Board of Directors effective November 1, 2026, and also named to the Board's Audit and Research Committees. Source 1 · Source 2
- On October 15, 2026, the company filed a notice regarding the removal of its 1.875% Notes due 2026. Source
- On October 29, 2026, the company reported third-quarter 2026 results, including GAAP EPS of $2.04 and non-GAAP EPS of $2.49. Source 1 · Source 2
- On October 29, 2026, the company announced a global license agreement with SciBrunch for the investigational oral KRAS G12D inhibitor SPR2015, incurring a $400 million R&D charge. Source
- On October 29, 2026, the company noted FDA approval of WELIREG plus Lenvima for renal cell carcinoma and European Commission approval of KEYTRUDA plus Padcev for bladder cancer. Source
- On October 29, 2026, Japan's Ministry of Health, Labor and Welfare approved the subcutaneous injection KEYJECT for all KEYTRUDA indications approved in Japan. Source
- On October 29, 2026, the company announced FDA acceptance of an sBLA for ENFLONSIA and a label update for WINREVAIR including data from the Phase 3 HYPERION trial. Source
- On October 29, 2026, the company announced the voluntary withdrawal of the Biologics License Application for ifinatamab deruxtecan in collaboration with Daiichi Sankyo. Source
- On October 29, 2026, the company presented results from the Phase 2b/3 BRUNELLO trial for Remigromig and announced positive Phase 2b results for Tulisokibart in patients with moderate to severe Hidradenitis Suppurativa. Source
- On October 29, 2026, the company recorded one-time R&D charges of $9.0 billion for the acquisition of Cidara Therapeutics, Inc. and $5.7 billion for the acquisition of Terns Pharmaceuticals, Inc. Source
Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.
Sector peers
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
Expectations and reality
Open
The Company established a goal to reach 100 million people with access solutions that close gaps in care by 2030.
Said October 29, 2026 · Period named: 2030 · Source · Our article
Not yet checked against later reports.
For full-year 2026, the company expects worldwide sales to be between $66.8 billion and $67.3 billion.
Said October 29, 2026 · Period named: Full-Year 2026 · Source · Our article
Not yet checked against later reports.
The Company anticipates full-year 2026 sales to be between $66.8 billion and $67.3 billion.
Said October 29, 2026 · Period named: full-year 2026 · Source · Our article
Not yet checked against later reports.
The Company expects full-year 2026 non-GAAP EPS to be between $2.77 and $2.82.
Said October 29, 2026 · Period named: full-year 2026 · Source · Our article
Not yet checked against later reports.
What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.
Governance events
Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.
| Date | Event | Filing |
|---|
| October 15, 2026 | Removal of a security from listing (Form 25) | 25-NSE |
| October 13, 2026 | Director or officer departure or appointment (8-K item 5.02) | 8-K |
As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.
Insider trades
| Date | Person | Trade | Shares | Avg. price | Value | Filing |
|---|
| November 12, 2026 | Richard R. DeLuca | Sale | 58,185 | $148.01 | $8,611,875 | SEC |
| November 12, 2026 | Richard Robert Deluca Jr | Planned sale | 58,185 | — | $8,611,875 | SEC |
| November 2, 2026 | David M Williams | Planned sale | 21,359 | — | $3,185,464 | SEC |
All insider trades →
Large funds (13F)
| Fund | Shares | Value | Change in shares | Quarter |
|---|
| BlackRock | 228,073,244 | $33,141,323,200 | +0.5% | Q3 2026 |
| State Street | 121,422,392 | $17,745,130,704 | +0.8% | Q3 2026 |
| Wellington Management | 71,664,541 | $10,413,574,452 | -16.9% | Q3 2026 |
| Geode Capital Management | 61,565,702 | $8,933,217,060 | +1.4% | Q3 2026 |
| Fidelity (FMR) | 46,222,051 | $6,716,526,284 | +1.7% | Q3 2026 |
| Norges Bank (Norway's sovereign fund) | 36,983,784 | $4,752,416,244 | — | Q2 2026 |
| Citadel Advisors | 3,323,725 | $482,970,480 | +71.9% | Q3 2026 |
| Millennium Management | 1,743,246 | $253,311,076 | +210.6% | Q3 2026 |
| D. E. Shaw & Co. | 808,713 | $117,514,086 | -70.5% | Q3 2026 |
| Capital Research Global Investors | 693,817 | $100,818,548 | -64.0% | Q3 2026 |
| Two Sigma Investments | 93,116 | $13,530,686 | +91.5% | Q3 2026 |
| Bridgewater Associates | 39,293 | $5,709,666 | +29.9% | Q3 2026 |
| T. Rowe Price | 26,603,959 | $3,865,822 | +43.7% | Q3 2026 |
| Renaissance Technologies | 4,357 | $632,802 | — | Q3 2026 |
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.